OJOG  Vol.5 No.7 , July 2015
Enhancement of Sister Chromatid Exchanges (SCEs) in Peripheral Blood Lymphocytes of Women with Polycystic Ovary Syndrome (PCOS) in Vitro
Abstract: The aim of the present study was to determine the level of underlying DNA damage in females with PCOS. Twenty-two women with PCOS and twenty-two healthy controls were included in this study. Patients were further categorized into three phenotypic subgroups: Subgroup A, oligo/anovulation (ANOV) and polycystic ovaries (PCO); Subgroup B, hyperandrogenism (HA) as a main characteristic (HA + ANOV or HA + PCO); Subgroup C, all three conditions present (HA + ANOV + PCO). The frequency of sister chromatid exchanges (SCEs) was used as an index of cytogenetic damage. Proliferation rate index (PRI), mitotic index (MI), average generation time (AGT) and population doubling time (PDT) were also evaluated. A significant (p < 0.01) increase in SCE levels along with a significant (p < 0.01) reduction in PRIs and MIs were observed in women with PCOS compared with healthy subjects. Additionally, subgroup C demonstrated statistically significant differences compared with others, while subgroup A had similar results with healthy females. Our results suggest that females with PCOS show increased chromosomal instability in peripheral lymphocytes and a consequent inability of the cells to promote their own mitotic cycle. A positive correlation between DNA damage and PCOS phenotypes is also reported.
Cite this paper: Dafa, E. , Kontou, M. , Mantratzi, T. , Kontomanolis, E. , Koutlaki, N. , Liberis, V. and Lialiaris, T. (2015) Enhancement of Sister Chromatid Exchanges (SCEs) in Peripheral Blood Lymphocytes of Women with Polycystic Ovary Syndrome (PCOS) in Vitro. Open Journal of Obstetrics and Gynecology, 5, 378-384. doi: 10.4236/ojog.2015.57055.

[1]   Sirmans, S.M. and Pate, K.A. (2013) Epidemiology, Diagnosis, and Management of Polycystic Ovary Syndrome. Clinical Epidemiology, 6, 1-13.

[2]   Azziz, R., Woods, K.S., Reyna, R., Key, T.J., Knochenhauer, E.S. and Yildiz, B.O. (2004) The Prevalence and Features of the Polycystic Ovary Syndrome in an Unselected Population. Journal of Clinical Endocrinology & Metabolism, 89, 2745-2749.

[3]   March, W.A., Moore, V.M., Willson, K.J., Phillips, D.I., Norman, R.J. and Davies, M.J. (2010) The Prevalence of Polycystic Ovary Syndrome in a Community Sample Assessed under Contrasting Diagnostic Criteria. Human Reproduction, 25, 544-551.

[4]   Yildiz, B.O., Bozdag, G., Yapici, Z., Esinler, I. and Yarali, H. (2012) Prevalence, Phenotype and Cardiometabolic Risk of Polycystic Ovary Syndrome under Different Diagnostic Criteria. Human Reproduction, 27, 3067-3073.

[5]   Barber, T.M. and Franks, S. (2013) Genetics of Polycystic Ovary Syndrome. Frontiers of Hormone Research, 40, 28-39.

[6]   Diamanti-Kandarakis, E., Kandarakis, H. and Legro, R.S. (2006) The Role of Genes and Environment in the Etiology of PCOS. Endocrine, 30, 19-26.

[7]   Franks, S., McCarthy, M.I. and Hardy, K. (2006) Development of Polycystic Ovary Syndrome: Involvement of Genetic and Environmental Factors. International Journal of Andrology, 29, 278-285.

[8]   Moran, L.J., Noakes, M., Clifton, P.M., Norman, R.J. and Fenech, M.F. (2008) Genome Instability Is Increased in Lymphocytes of Women with Polycystic Ovary Syndrome and Is Correlated with Insulin Resistance. Mutation Research, 639, 55-63.

[9]   Nersesyan, A., Martirosyan, A., Parsadanyan, G. and Zalinyan, G. (2006) Chromosomal Aberrations Level in Peripheral Blood Lymphocytes of Women with Polycystic Ovary Syndrome. Journal of the Balkan Union of Oncology, 11, 477-480.

[10]   Yesilada, E., Sahin, I., Ozcan, H., Yildirim, I.H., Yologlu, S. and Taskapan, C. (2006) Increased Micronucleus Frequencies in Peripheral Blood Lymphocytes in Women with Polycystic Ovary Syndrome. European Journal of Endocrinology, 154, 563-568.

[11]   Hague, W.M., Adams, J., Reeders, S.T. and Jacobs, H.S. (1989) 45 X Turner’s Syndrome in Association with Polycystic Ovaries. Case Report. British Journal of Obstetrics and Gynaecology, 96, 613-618.

[12]   Wilson III, D.M. and Thompson, L.H. (2007) Molecular Mechanisms of Sister Chro-Matid Exchange. Mutation Research, 616, 11-23.

[13]   Lasne, C., Gu, Z.W., Venegas, W. and Chouroulinkov, I. (1984) The in Vitro Micro-Nucleus Assay for Detection of Cytogenetic Effects Induced by Mutagen-Carcinogens: Comparison with the in Vitro Sister-Chromatid Exchange Assay. Mutation Research, 130, 273-282.

[14]   Maskaleris, T., Lialiaris, T. and Triantaphyllidis, C. (1998) Induction of Cytogenetic Damage in Human Lymphocytes in Vitro and of Antineoplastic Effects in Ehrlich Ascites Tumor Cells in Vivo Treated by Methotrexate, Hyperthermia and/or Caffeine. Mutation Research, 422, 229-236.

[15]   Lialiaris, T., Mourelatos, D. and Dozi-Vassiliades, J. (1988) Enhancement of Cytoge-Netic Damage by Chlorpromazine in Human Lymphocytes Treated with Alkylating Antineoplastics and Caffeine. Mutation Research, 206, 361-365.

[16]   Mathijssen, R.H., Loos, W.J., Verweii, J. and Sparreboom, A. (2002) Pharmacology of Topoisomerase I Inhibitors Irinotecan (CPT-11) and Topotecan. Current Cancer Drug Targets, 2, 103-123.

[17]   Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 Consensus on Diagnostic Criteria and Long-Term Health Risks Related to Polycystic Ovary Syndrome (PCOS). Fertility Sterility, 81, 19-25.

[18]   Avani, G. and Rao, M.V. (2007) Genotoxic Effects in Human Lymphocytes Exposed to Arsenic and Vitamin A. Toxicology in Vitro, 21, 626-631.

[19]   Nersesyan, A. and Chobanyan, N. (2010) Micronuclei and Other Nuclear Anomalies Levels in Exfoliated Buccal Cells and DNA Damage in Leukocytes of Patients with Polycystic Ovary Syndrome. Journal of the Balkan Union of Oncology, 15, 337-339.

[20]   Hamurcu, Z., Bayram, F., Kahriman, G., Donmez-Altuntas, H. and Baskol, G. (2010) Micronucleus Frequency in Lymphocytes and 8-Hydroxydeoxyguanosine Level in Plasma of Women with Polycystic Ovary Syndrome. Gynecological Endocrinology, 26, 590-595.

[21]   Wenger, L.S. (1995) Chemical Induction of Sister Chromatid Exchange at Fragile Sites. Cancer Genetics and Cytogenetics, 85, 72-74.

[22]   Manikkumar, R., Roy, D.D., Krishnan, V. and Vijayakumar, T. (2013) Association of DNA Damage and Dyslipidemia with Polycystic Ovarian Syndrome. Journal of Medical & Allied Sciences, 3, 15-21.

[23]   Kopjar, N., Zeljezic, D., Vrdoljak, A.L., Radic, B., Ramic, S., Milic, M., Gamulin, M., Pavlica, V. and Fucic, A. (2007) Irinotecan Toxicity to Human Blood Cells in Vitro: Relationship between Various Biomarkers. Basic & Clinical Pharmacology & Toxicology, 100, 403-413.

[24]   Dinger, Y., Akcay, T., Erdem, T., IIkerSayqili, E. and Gundogdu, S. (2005) DNA Damage, DNA Susceptibility to Oxidation and Glutathione Level in Women with Poly-Cystic Ovary Syndrome. Scandinavian Journal of Clinical and Laboratory Investigation, 65, 721-728.

[25]   Gallo, M., Aragno, M., Gatto, V., Tamagno, E., Brignardello, E. and Manti, R. (1999) Protective Effect of Dehydroepiandrosterone against Lipid Peroxidation in Human Liver Cell Line. European Journal of Endocrinology, 141, 35-39.

[26]   Chainy, G.B.N., Samantaray, S. and Samanta, L. (1997) Testosterone Induced Changes in Testicular Antioxidant System. Andrologia, 29, 343-349.

[27]   Migliore, L. and Coppede, F. (2002) Genetic and Environmental Factors in Cancer Neurodegenerative DISEASES. Mutation Research, 512, 135-153.

[28]   Hassold, T., Chen, N., Funkhouser, J., Jooss, T., Manuel, B., Matsuura, J., Matsu-yama, A., Wilson, C., Yamane, J.A. and Jacobs, P.A. (1980) A Cytogenetic Study of 1000 Spontaneous Abortions. Annals of Humans Genetics, 44, 151-178.

[29]   Gadducci,A., Gargini, A., Palla, E., Fanucchi, A. and Genazzani, A.R. (2005) Poly-Cystic Ovary Syndrome and Gynecological Cancers: Is There a Link? Gynecological Endocrinology, 20, 200-208.

[30]   Sagle, M., Bishop, K., Ridley, N., Alexander, F.M., Michel, M., Bonney, R.C., Beard, R.W. and Franks, S. (1988) Recurrent Early Miscarriage and Polycystic Ovaries. British Medical Journal, 297, 1027-1028.

[31]   Dumesic, D.A. and Lobo, R.A. (2013) Cancer Risk and PCOS. Steroids, 78, 782-785.

[32]   Baltaci, V., Kayikcioglu, F., Alpas, I., Zeyneloglu, H. and Haberal, A. (2002) Sister Chromatid Exchange Rate and Alkaline Comet Assay Scores in Patients with Ovarian Cancer. Gynecological Oncology, 84, 62-66.

[33]   Dhar, P.K., Devi, S., Rao, T.R., Kumari, U., Joseph, A., Kumar, M.R., Nayak, S., Shreemati, Y., Bhat, S.M. and Bhat, K.R. (1996) Significance of Lymphocytic Sister Chromatid Exchange Frequencies in Ovarian Cancer Patients. Cancer Genetics and Cytogenetics, 89, 105-108.